Alnylam Pharmaceuticals, Inc. (LON:0HD2)
269.42
-1.09 (-0.40%)
Mar 28, 2025, 7:22 PM BST
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
805.30K GBP
Profits / Employee
-99.63K GBP
Market Cap
26.85B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 25,408 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,988 |
Genus | 3,500 |
Alnylam Pharmaceuticals News
- 2 days ago - Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 - Business Wire
- 2 days ago - FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B - Business Wire
- 3 days ago - siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials - GlobeNewsWire
- 7 days ago - Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - Benzinga
- 9 days ago - Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster - Seeking Alpha
- 10 days ago - Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps - Benzinga
- 10 days ago - Alnylam shares rise on expanded heart drug approval - Reuters
- 10 days ago - US FDA approves Alnylam's drug for rare heart condition - Reuters